Hitech Windlass, Managing Director of Windlass Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.IPO-bound Windlass Biotech plans to build CDMO injectable biz, trade generics
Hitech Windlass, Managing Director of Windlass Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment